These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 11336575)

  • 1. Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis.
    Davies NM; Gudde TW; de Leeuw MA
    Expert Opin Pharmacother; 2001 Jan; 2(1):139-52. PubMed ID: 11336575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
    Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G
    N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.
    Goldenberg MM
    Clin Ther; 1999 Sep; 21(9):1497-513; discussion 1427-8. PubMed ID: 10509845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention comes to clinical practice: COX-2 inhibition in familial adenomatous polyposis.
    Bresalier RS
    Gastroenterology; 2000 Dec; 119(6):1797-8. PubMed ID: 11113106
    [No Abstract]   [Full Text] [Related]  

  • 5. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
    Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
    Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celecoxib clinical profile.
    Tive L
    Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():21-8; discussion 57-9. PubMed ID: 11276798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arthritis drug approved for polyp prevention blazes trail for other prevention trials.
    Smigel K
    J Natl Cancer Inst; 2000 Feb; 92(4):297-9. PubMed ID: 10675374
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor.
    Davies NM; McLachlan AJ; Day RO; Williams KM
    Clin Pharmacokinet; 2000 Mar; 38(3):225-42. PubMed ID: 10749518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
    Jüni P; Rutjes AW; Dieppe PA
    BMJ; 2002 Jun; 324(7349):1287-8. PubMed ID: 12039807
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
    Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
    JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of celecoxib, a COX-2 inhibitor, in familial adenomatous polyposis].
    Wullen B; Mühlhöfer A; Zoller WG
    Z Gastroenterol; 2001 Apr; 39(4):335-7. PubMed ID: 11367984
    [No Abstract]   [Full Text] [Related]  

  • 14. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
    Spiegel BM; Targownik L; Dulai GS; Gralnek IM
    Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual disturbance associated with celecoxib.
    Lund BC; Neiman RF
    Pharmacotherapy; 2001 Jan; 21(1):114-5. PubMed ID: 11191731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
    Ann Intern Med; 2003 May; 138(10):I39. PubMed ID: 12755582
    [No Abstract]   [Full Text] [Related]  

  • 17. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
    Kismet K; Akay MT; Abbasoglu O; Ercan A
    Cancer Detect Prev; 2004; 28(2):127-42. PubMed ID: 15068837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Celecoxib: a COX-2 inhibitor.
    Andrews SA; Wallace CK; Davis RL
    Am J Manag Care; 1999 Apr; 5(4):511-8; quiz 522-4. PubMed ID: 10387389
    [No Abstract]   [Full Text] [Related]  

  • 19. COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile?
    Simon LS
    Gastroenterol Clin North Am; 2001 Dec; 30(4):1011-25, viii. PubMed ID: 11764530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
    Moore PA; Hersh EV
    J Am Dent Assoc; 2001 Apr; 132(4):451-6. PubMed ID: 11315375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.